	US 12,109,259 B2
	Vaccines for Neisseria gonorrhoeae
Mariagrazia Pizza, Siena (IT); and Steven B. Black, Berkeley (CA)
Assigned to GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Appl. No. 16/326,833
Filed by GLAXOSMITHKLINE BIOLOGICALS, S.A., Rixensart (BE)
PCT Filed Sep. 1, 2017, PCT No. PCT/EP2017/072009 § 371(c)(1), (2) Date Feb. 20, 2019, PCT Pub. No. WO2018/042015, PCT Pub. Date Mar. 8, 2018.
Claims priority of provisional application 62/383,134, filed on Sep. 2, 2016.
Prior Publication US 2019/0282684 A1, Sep. 19, 2019
Int. Cl. A61K 39/095 (2006.01); A61K 39/116 (2006.01); A61K 39/39 (2006.01); A61K 47/64 (2017.01); C07K 14/22 (2006.01); C07K 16/12 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/095 (2013.01) [A61K 39/116 (2013.01); A61K 39/39 (2013.01); A61K 47/646 (2017.08); C07K 14/22 (2013.01); C07K 16/1217 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/58 (2013.01); C07K 2317/33 (2013.01)]

16 Claims

1. A method for immunizing a subject against Neisseria gonorrhoeae by administering to the subject an immunogenic composition according to a multiple dose schedule, the method comprising:

administering to the subject the immunogenic composition, wherein the immunogenic composition comprises meningococcal outer membrane vesicles (OMVs) from Neisseria meningitidis serogroup B strain NZ98/254; and

administering the immunogenic composition to the subject to induce a cross-reactive immune response against Neisseria gonorrhoeae, wherein the subject is 12 to 18 or 18 years or older and is at increased risk of infection with Neisseria gonorrhoeae relative to the average risk in the general population, and

wherein the subject has been previously immunized against N. meningitidis, and wherein the immunogenic composition is used to treat Neisseria gonorrhoeae in the subject.